Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
435 participants
INTERVENTIONAL
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
NCT00768521
A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
NCT00966004
Study of ONO-8577 in Patients With Overactive Bladder
NCT03106623
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
NCT01604928
Effect of Long Acting Anticholinergic on Nocturnal Incontinence After Radical Cystectomy and Orthotopic Neobladder
NCT02877901
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
P
Placebo
Placebo / 12 weeks
A
Tolterodine
4mg / 12 weeks
E1
ONO-8539
low dose / 12 weeks
E2
ONO-8539
medium dose / 12 weeks
E3
ONO-8539
higher dose / 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo / 12 weeks
Tolterodine
4mg / 12 weeks
ONO-8539
low dose / 12 weeks
ONO-8539
medium dose / 12 weeks
ONO-8539
higher dose / 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ono Pharmaceutical Co. Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tomohiro Kuwayama
Role: STUDY_DIRECTOR
Clinical Development, ONO Pharma UK, Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brno, , Czechia
Jindřichův Hradec, , Czechia
Olomouc, , Czechia
Opava, , Czechia
Pilsen, , Czechia
Prague, , Czechia
Štětí, , Czechia
Ústí nad Labem, , Czechia
Duisburg, , Germany
Hagenow, , Germany
Krumbach, , Germany
Magdeburg, , Germany
Mülheim, , Germany
Weiden, , Germany
Budapest, , Hungary
Dombóvár, , Hungary
Nyíregyháza, , Hungary
Szeged, , Hungary
Szekszárd, , Hungary
Heerlen, , Netherlands
Maastricht, , Netherlands
The Hague, , Netherlands
Tilburg, , Netherlands
Winterswijk, , Netherlands
Bialystok, , Poland
Bielsko-Biala, , Poland
Gdansk, , Poland
Gdynia, , Poland
Katowice, , Poland
Lodz, , Poland
Lublin, , Poland
Mysłowice, , Poland
Warsaw, , Poland
Arad, , Romania
Bihor, , Romania
Bucharest, , Romania
Timuș, , Romania
Moscow, , Russia
Rostov-on-Don, , Russia
Saint Petersburg, , Russia
Gothenburg, , Sweden
Kungälv, , Sweden
Stockholm, , Sweden
Umeå, , Sweden
Uppsala, , Sweden
Chernivtsi, , Ukraine
Donetsk, , Ukraine
Kharkiv, , Ukraine
Kyiv, , Ukraine
Zaporizhzhya, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ONO-8539POE004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.